Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q92925

UPID:
SMRD2_HUMAN

ALTERNATIVE NAMES:
60 kDa BRG-1/Brm-associated factor subunit B; BRG1-associated factor 60B

ALTERNATIVE UPACC:
Q92925; A5PLL5; A6NNQ7; B4DV56; B4E1R6; Q7L2I6; Q9UHZ1

BACKGROUND:
The protein SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 2, also known as BRG1-associated factor 60B, is integral to the process of chromatin remodeling. It facilitates transcriptional activation and repression by altering the structure of chromatin, thus playing a critical role in gene expression and cellular differentiation, particularly in the myeloid lineage.

THERAPEUTIC SIGNIFICANCE:
Mutations in the gene encoding SWI/SNF are causative for Specific granule deficiency 2, a condition marked by impaired neutrophil function and development. The exploration of SWI/SNF's function offers promising avenues for the development of novel treatments for hematological disorders and immune deficiencies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.